8-K Announcements
6Material company update
Apr 23, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Mar 2, 2026·SEC
Day One Biopharmaceuticals, Inc.(DAWN)Earnings, Financials & Key Ratios
DAWN•NASDAQ
Price updated May 8, 2026
AboutDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Show more
- Revenue$158M+20.6%
- EBITDA-$124M+42.3%
- Net Income-$107M-12.4%
- EPS (Diluted)-1.04-2.0%
- Gross Margin89.12%-7.1%
- EBITDA Margin-78.56%+52.1%
- Operating Margin-80.76%+51.2%
- Net Margin-67.85%+6.8%
- ROE-22.74%-1.1%
DAWN Key Insights
Day One Biopharmaceuticals, Inc. (DAWN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 96 (top 4%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 21.5% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 10.4% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DAWN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DAWN Price & Volume
Day One Biopharmaceuticals, Inc. (DAWN) stock price & volume — 10-year historical chart
Loading chart...
DAWN Growth Metrics
Day One Biopharmaceuticals, Inc. (DAWN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM20.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-12.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM4.64%
Return on Capital
10 Years-47.1%
5 Years-46.17%
3 Years-46.06%
Last Year-26.71%
DAWN Recent Earnings
Day One Biopharmaceuticals, Inc. (DAWN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 4/12 qtrs (57%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.35-12.9%
$0.31
Rev
—
$54M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.20-17.6%
$0.17
Rev
$54M+7.7%
$50M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.19+31.8%
$0.28
Rev
$40M+4.2%
$38M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.29+17.1%
$0.35
Rev
$34M-14.4%
$40M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.35vs $0.31-12.9% | —vs $54M |
| Q1 2026 | Feb 24, 2026 | $0.20vs $0.17-17.6% | $54Mvs $50M+7.7% |
| Q4 2025 | Nov 4, 2025 | $0.19vs $0.28+31.8% | $40Mvs $38M+4.2% |
| Q3 2025 | Aug 5, 2025 | $0.29vs $0.35+17.1% | $34Mvs $40M-14.4% |
Based on last 12 quarters of dataView full earnings history →
DAWN Peer Comparison
Day One Biopharmaceuticals, Inc. (DAWN) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KURA | 881.53M | 9.93 | -3.12 | 25.24% | -411.19% | -141.95% | 0.12 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ERAS | 4.25B | 13.67 | -31.07 | -77.01% | 0.14 |
Compare DAWN vs Peers
Day One Biopharmaceuticals, Inc. (DAWN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DAWN Income Statement
Day One Biopharmaceuticals, Inc. (DAWN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 131.16M | 158.18M |
Revenue Growth % | - | - | - | - | - | - | 20.6% |
Cost of Goods Sold | 0 | 155K | 199K | 531K | 383K | 5.28M | 17.21M |
COGS % of Revenue | - | - | - | - | - | 4.02% | 10.88% |
Gross Profit | 0▲ 0% | -155K▲ 0% | -199K▼ 28.4% | -531K▼ 166.8% | -383K▲ 27.9% | 125.88M▲ 32967.4% | 140.97M▲ 12.0% |
Gross Margin % | - | - | - | - | - | 95.98% | 89.12% |
Gross Profit Growth % | - | - | -28.39% | -166.83% | 27.87% | 32967.36% | 11.99% |
Operating Expenses | 14.9M | 13.63M | 72.54M | 146.38M | 205.68M | 343.15M | 268.72M |
OpEx % of Revenue | - | - | - | - | - | 261.63% | 169.88% |
Selling, General & Admin | 1.01M | 4.53M | 28.96M | 60.76M | 75.16M | 115.45M | 120.59M |
SG&A % of Revenue | - | - | - | - | - | 88.02% | 76.23% |
Research & Development | 13.9M | 9.1M | 43.58M | 85.62M | 130.52M | 227.7M | 148.13M |
R&D % of Revenue | - | - | - | - | - | 173.61% | 93.65% |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -14.9M▲ 0% | -13.78M▲ 7.5% | -72.74M▼ 427.8% | -146.91M▼ 102.0% | -206.06M▼ 40.3% | -217.27M▼ 5.4% | -127.75M▲ 41.2% |
Operating Margin % | - | - | - | - | - | -165.65% | -80.76% |
Operating Income Growth % | - | 7.53% | -427.81% | -101.96% | -40.27% | -5.44% | 41.2% |
EBITDA | 0 | -13.63M | -72.54M | -146.38M | -205.68M | -215.24M | -124.27M |
EBITDA Margin % | - | - | - | - | - | -164.1% | -78.56% |
EBITDA Growth % | - | - | -432.35% | -101.78% | -40.51% | -4.65% | 42.26% |
D&A (Non-Cash Add-back) | 14.9M | 155K | 199K | 531K | 383K | 2.03M | 3.48M |
EBIT | -14.91M | -43.81M | -72.75M | -142.18M | -188.92M | -88.35M | -109.3M |
Net Interest Income | -2.08M | -30K | 4K | 4.75M | 17.19M | 19.7M | 18.47M |
Interest Income | 0 | 0 | 4K | 4.75M | 17.19M | 19.7M | 18.47M |
Interest Expense | 2.08M | 30K | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -2.08M | -30.06M | -11K | 4.73M | 17.15M | 128.92M | 18.45M |
Pretax Income | -16.98M▲ 0% | -43.84M▼ 158.1% | -72.75M▼ 65.9% | -142.18M▼ 95.4% | -188.92M▼ 32.9% | -88.35M▲ 53.2% | -109.3M▼ 23.7% |
Pretax Margin % | - | - | - | - | - | -67.36% | -69.1% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 7.14M | -1.98M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -8.09% | 1.81% |
Net Income | -12.63M▲ 0% | -40.51M▼ 220.6% | -70.64M▼ 74.4% | -142.18M▼ 101.3% | -188.92M▼ 32.9% | -95.5M▲ 49.5% | -107.32M▼ 12.4% |
Net Margin % | - | - | - | - | - | -72.81% | -67.85% |
Net Income Growth % | - | -220.62% | -74.4% | -101.26% | -32.87% | 49.45% | -12.38% |
Net Income (Continuing) | -16.98M | -43.84M | -72.75M | -142.18M | -188.92M | -95.5M | -107.32M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 5.49M | 5.7M | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.24▲ 0% | -0.65▼ 170.8% | -1.14▼ 75.4% | -2.02▼ 77.2% | -2.37▼ 17.3% | -1.02▲ 57.0% | -1.04▼ 2.0% |
EPS Growth % | - | -170.83% | -75.38% | -77.19% | -17.33% | 56.96% | -1.96% |
EPS (Basic) | -0.24 | -0.65 | -1.14 | -2.02 | -2.37 | -1.02 | -1.04 |
Diluted Shares Outstanding | 61.93M | 61.93M | 61.95M | 65.47M | 79.77M | 93.62M | 103.38M |
Basic Shares Outstanding | 61.93M | 61.93M | 61.95M | 65.47M | 79.77M | 93.62M | 103.38M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
DAWN Balance Sheet
Day One Biopharmaceuticals, Inc. (DAWN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
Total Current Assets | 27.34M | 45.07M | 289.37M | 347.87M | 375.27M | 562.33M | 485.1M |
Cash & Short-Term Investments | 27.33M | 43.73M | 284.31M | 342.27M | 366.35M | 531.72M | 441.11M |
Cash Only | 27.33M | 43.73M | 284.31M | 85.26M | 230.78M | 124.97M | 197.08M |
Short-Term Investments | 0 | 0 | 0 | 257.01M | 135.56M | 406.75M | 244.03M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 13.88M | 26.73M |
Days Sales Outstanding | - | - | - | - | - | 38.61 | 61.69 |
Inventory | 0 | 0 | 0 | 0 | 0 | 3.32M | 6.33M |
Days Inventory Outstanding | - | - | - | - | - | 229.62 | 134.17 |
Other Current Assets | 0 | 1.26M | 1.01M | 1.01M | 2.35M | 4.37M | 10.93M |
Total Non-Current Assets | 0 | 590K | 453K | 1.19M | 774K | 20.46M | 22.73M |
Property, Plant & Equipment | 0 | 483K | 284K | 719K | 560K | 4.71M | 4.48M |
Fixed Asset Turnover | - | - | - | - | - | 27.87x | 35.32x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 15.63M | 18.02M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 107K | 169K | 469K | 214K | 121K | 230K |
Total Assets | 27.34M▲ 0% | 45.66M▲ 67.0% | 289.82M▲ 534.7% | 349.06M▲ 20.4% | 376.05M▲ 7.7% | 582.79M▲ 55.0% | 507.83M▼ 12.9% |
Asset Turnover | - | - | - | - | - | 0.23x | 0.31x |
Asset Growth % | - | 67.02% | 534.72% | 20.44% | 7.73% | 54.98% | -12.86% |
Total Current Liabilities | 2.02M | 2M | 8.66M | 16.61M | 29.51M | 73.45M | 60.52M |
Accounts Payable | 69K | 202K | 1.74M | 260K | 2.58M | 3.26M | 3.73M |
Days Payables Outstanding | - | 475.68 | 3.2K | 178.72 | 2.45K | 225.54 | 79.17 |
Short-Term Debt | 0 | 0 | 204K | 405K | 408K | 10K | 174K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 1.55M | 2M |
Other Current Liabilities | 1.49M | 27K | 104K | 9.82M | 17.36M | 54.68M | 54.62M |
Current Ratio | 13.53x | 22.58x | 33.43x | 20.94x | 12.72x | 7.66x | 8.02x |
Quick Ratio | 13.53x | 22.58x | 33.43x | 20.94x | 12.72x | 7.61x | 7.91x |
Cash Conversion Cycle | - | - | - | - | - | 42.69 | 116.68 |
Total Non-Current Liabilities | 30.5M | 204K | 16K | 408K | 0 | 6.59M | 6.14M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 2.62M |
Capital Lease Obligations | 0 | 204K | 16K | 408K | 0 | 2.59M | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 30.5M | 0 | 0 | 0 | 0 | 761K | 3.52M |
Total Liabilities | 32.52M | 2.2M | 8.67M | 17.02M | 29.51M | 80.04M | 66.67M |
Total Debt | 0 | 402K | 220K | 813K | 408K | 2.6M | 2.79M |
Net Debt | -27.33M | -43.33M | -284.09M | -84.45M | -230.38M | -122.37M | -194.28M |
Debt / Equity | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - |
Interest Coverage | -7.18x | -1460.43x | - | - | - | - | - |
Total Equity | -5.19M▲ 0% | 43.46M▲ 938.0% | 281.15M▲ 546.9% | 332.04M▲ 18.1% | 346.54M▲ 4.4% | 502.75M▲ 45.1% | 441.16M▼ 12.3% |
Equity Growth % | - | 938.04% | 546.9% | 18.1% | 4.37% | 45.08% | -12.25% |
Book Value per Share | -0.08 | 0.70 | 4.54 | 5.07 | 4.34 | 5.37 | 4.27 |
Total Shareholders' Equity | -10.67M | 37.76M | 281.15M | 332.04M | 346.54M | 502.75M | 441.16M |
Common Stock | 2M | 2.64M | 6K | 7K | 9K | 10K | 10K |
Retained Earnings | -12.78M | -56.84M | -127.49M | -269.67M | -458.58M | -554.08M | -661.4M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 111 | 0 | 0 | -71K | 9K | 84K | 65K |
Minority Interest | 5.49M | 5.7M | 0 | 0 | 0 | 0 | 0 |
DAWN Cash Flow Statement
Day One Biopharmaceuticals, Inc. (DAWN) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
Cash from Operations | -4.51M | -13.49M | -48.54M | -109.87M | -146.85M | -78.11M | -103.76M |
Operating CF Margin % | - | - | - | - | - | -59.56% | -65.59% |
Operating CF Growth % | - | -198.76% | -259.84% | -126.36% | -33.66% | 46.81% | -32.83% |
Net Income | -16.98M | -43.84M | -72.75M | -142.18M | -188.92M | -95.5M | -107.32M |
Depreciation & Amortization | 0 | 155K | 199K | 531K | 383K | 2.03M | 3.48M |
Stock-Based Compensation | 111K | 526K | 13.32M | 27.24M | 39.34M | 48.26M | 44.39M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 11.91M | 30.03M | 8M | -2.03M | -7.08M | -59.39M | -15.36M |
Working Capital Changes | 444K | -357K | 2.69M | 6.56M | 9.42M | 26.48M | -28.94M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | -13.88M | -12.86M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | -3.24M | -2.86M |
Change in Payables | 14K | 132K | 1.54M | -1.48M | 2.32M | 686K | 471K |
Cash from Investing | 0 | -92K | -8M | -255.07M | 128.38M | -230.99M | 174.65M |
Capital Expenditures | 0 | -92K | -8M | -26K | -224K | -2.17M | -320K |
CapEx % of Revenue | - | - | - | - | - | 1.65% | 0.2% |
Acquisitions | 0 | 0 | 0 | 255.05K | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -255.05K | -3M | 35.9M | -3.47M |
Cash from Financing | 30.91M | 29.98M | 297.12M | 165.9M | 164M | 203.29M | 1.22M |
Debt Issued (Net) | 1M | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 29.91M | 29.98M | 296.8M | 161.61M | 164M | 178.18M | 1.22M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 318K | 4.29M | 0 | 25.11M | 0 |
Net Change in Cash | 26.39M▲ 0% | 16.4M▼ 37.9% | 240.58M▲ 1367.3% | -199.05M▼ 182.7% | 145.52M▲ 173.1% | -105.82M▼ 172.7% | 72.11M▲ 168.1% |
Free Cash Flow | -4.51M▲ 0% | -13.58M▼ 200.8% | -56.54M▼ 316.3% | -109.9M▼ 94.4% | -150.08M▼ 36.6% | -80.28M▲ 46.5% | -104.08M▼ 29.6% |
FCF Margin % | - | - | - | - | - | -61.21% | -65.8% |
FCF Growth % | - | -200.8% | -316.31% | -94.38% | -36.56% | 46.51% | -29.64% |
FCF per Share | -0.07 | -0.22 | -0.91 | -1.68 | -1.88 | -0.86 | -1.01 |
FCF Conversion (FCF/Net Income) | 0.36x | 0.33x | 0.69x | 0.77x | 0.78x | 0.82x | 0.97x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 1.9M | 0 |
DAWN Key Ratios
Day One Biopharmaceuticals, Inc. (DAWN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -211.66% | -43.53% | -46.37% | -55.68% | -22.49% | -22.74% |
Return on Invested Capital (ROIC) | - | - | - | -90.07% | -84.97% | -65.63% | -30.55% |
Gross Margin | - | - | - | - | - | 95.98% | 89.12% |
Net Margin | - | - | - | - | - | -72.81% | -67.85% |
Debt / Equity | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x |
Interest Coverage | -7.18x | -1460.43x | - | - | - | - | - |
FCF Conversion | 0.36x | 0.33x | 0.69x | 0.77x | 0.78x | 0.82x | 0.97x |
Revenue Growth | - | - | - | - | - | - | 20.6% |
Related:DAWN Dividend History·DAWN Revenue History·DAWN Price History·DAWN P/E History·DAWN Financial Ratios·DAWN Institutional Holders
DAWN SEC Filings & Documents
Day One Biopharmaceuticals, Inc. (DAWN) SEC filings — annual & quarterly reports (10-K, 10-Q)
DAWN Frequently Asked Questions
Day One Biopharmaceuticals, Inc. (DAWN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Day One Biopharmaceuticals, Inc. (DAWN) reported $158.2M in revenue for fiscal year 2025.
Day One Biopharmaceuticals, Inc. (DAWN) grew revenue by 20.6% over the past year. This is strong growth.
Day One Biopharmaceuticals, Inc. (DAWN) reported a net loss of $107.3M for fiscal year 2025.
Dividend & Returns
Day One Biopharmaceuticals, Inc. (DAWN) has a return on equity (ROE) of -22.7%. Negative ROE indicates the company is unprofitable.
Day One Biopharmaceuticals, Inc. (DAWN) had negative free cash flow of $107.6M in fiscal year 2025, likely due to heavy capital investments.